Milestone Pharma Q1 operating loss $15M; etripamil NDA on track for Q3 2023

Milestone Pharmaceuticals Inc.

2023-Q1 EPS reported -$0.35

Cash of $101M as of March 31, 2023; with $125M RTW financing, runway into mid-2025.
NDA submission for etripamil (PSVT) to FDA remains on track for Q3 2023.
Phase 2 ReVeRA trial (AFib-RVR) topline data expected H2 2023.
Appointed Seth H.Z. Fischer to Board of Directors in March 2023.
Operating loss of $15.0M in Q1 2023 vs. $14.0M in Q1 2022; R&D expense rose to $10.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Milestone Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023, which also provided a clinical and corporate update.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-058749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.